The FDA recently approved Genentech’s Lucentis (ranibizumab injection) for the monthly treatment of all forms of diabetic retinopathy (DR). The recent approval came after a Priority Review based on an analysis of the’s Protocol S study. The study compared Lucentis treatment with panretinal laser photocoagulation in DR patients with and without DME, and found the Lucentis group experienced improvements in retinopathy severity.

Genentech. FDA approves Genentech's Lucentis (ranibizumab Injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States. April 17, 2017.